Join
Live feed
·
PRReleasevia Quantisnow
Protara Therapeutics Inc. logo

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

ByQuantisnow·Wall Street's wire, on your screen.
TARA· Protara Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TARA (Protara Therapeutics Inc.) and more on Quantisnow.